At Flow Wellness, we are always watching for emerging science that may benefit our patients’ long-term health—not just through weight loss, but through the prevention of chronic diseases. A new study from Case Western Reserve University is offering hopeful news for families affected by Alzheimer’s disease.
In this large-scale study of nearly 1.7 million people with type 2 diabetes, those taking semaglutide (the active ingredient in Ozempic and Wegovy) had a significantly lower risk of developing dementia compared to those on seven other common diabetes medications. This effect was especially strong in older adults and women, who are disproportionately affected by Alzheimer’s.
This is not just lab data—it’s real-world evidence based on health records collected over three years. While the study doesn’t yet prove causation, it adds to a growing body of evidence suggesting that semaglutide may have neuroprotective effects in addition to helping with weight loss, blood sugar regulation, and metabolic health. Please note this studied was performed in people with Type 2 diabetes.
Even more promising: two large, placebo-controlled clinical trials (EVOKE and EVOKE PLUS) are currently underway to investigate whether semaglutide can slow cognitive decline in people with early-stage Alzheimer’s. Results are expected later this year.
Why does this matter? Many dementia cases are linked to modifiable risk factors such as obesity, diabetes, insulin resistance, cardiovascular disease, and chronic inflammation—all areas where GLP-1 medications like semaglutide have shown benefits.
If future studies confirm these findings, semaglutide could represent a groundbreaking shift in how we prevent and manage not only obesity, but also cognitive decline and Alzheimer’s.
At Flow Wellness, we are committed to staying at the forefront of this research and bringing our patients evidence-based therapies that support brain and body health.
More information about the study here.